91΄σΟγ½Ά

91΄σΟγ½Ά
91΄σΟγ½Ά 91΄σΟγ½Ά
Research Group Lab Hall
Pharmacology and Toxicology
John Auchampach, PhD

John A. Auchampach, PhD

Professor and Vice-Chair

Locations

  • Pharmacology and Toxicology

Contact Information

General Interests

Cardiovascular Pharmacology

Education

PhD, Pharmacology and Toxicology, 91΄σΟγ½Ά, 1992
BS, Pharmacy, South Dakota State University, 1988

Research Experience

  • Adenosine
  • Cardiovascular Diseases
  • Drug Design
  • Heart Failure
  • Inflammation
  • Myocardial Infarction
  • Purines
  • Receptors, G-Protein-Coupled
  • Receptors, Purinergic P1
  • Regeneration
  • Signal Transduction

Research Interests

Adenosine production by cells is increased when cellular energy utilization and the breakdown of adenosine tri-phosphate (ATP) is increased. Thus, adenosine levels are elevated in tissues when there is not enough oxygen in the cells or during other pathological processes involving cellular stress, inflammation, and tissue injury. Through interaction with four related receptors termed A1, A2A, A2B, and A3 adenosine receptors - proteins found on the surface of cells that recognize adenosine and related ligands - adenosine affects many different disease processes, ranging from ischemic heart disease to cancer.

We are investigating the biological function of the two least understood adenosine receptor subtypes, the A2B and A3 adenosine receptors. In particular, the team is investigating how the A3 adenosine receptor modulates activity of certain immune cells and helps to protect the heart from ischemia/reperfusion injury, known commonly as a heart attack. As part of this project, new ligands for the A3 adenosine receptor are being developed, including novel allosteric modulator compounds that enhance the ability of the receptor to be activated by binding to a region that is distinctly different than the binding site for adenosine. In a second project, we are investigating the novel hypothesis that the A2B adenosine receptor contributes to stiffening of the heart during certain chronic cardiovascular diseases that lead to heart failure by promoting the formation of excess connective tissue, a pathological process termed cardiac fibrosis. A basic understanding of the function of each of the adenosine receptors is anticipated to identify new approaches for the treatment of a wide range of diseases.

Publications

  • (Pradhan B, Pavan M, Fisher CL, Salmaso V, Wan TC, Keyes RF, Rollison N, Suresh RR, Kumar TS, Gao ZG, Smith BC, Auchampach JA, Jacobson KA.) J Med Chem. 2024 Jul 25;67(14):12221-12247 PMID: 38959401 SCOPUS ID: 2-s2.0-85197620924 07/03/2024

  • (Fisher CL, Pavan M, Salmaso V, Keyes RF, Wan TC, Pradhan B, Gao ZG, Smith BC, Jacobson KA, Auchampach JA.) Mol Pharmacol. 2024 Feb 15;105(3):213-223 PMID: 38182432 PMCID: PMC10877738 SCOPUS ID: 2-s2.0-85185222449 01/06/2024

  • (Wang X, Kulik K, Wan TC, Lough JW, Auchampach JA.) bioRxiv. 2024 Jan 13 PMID: 38260622 PMCID: PMC10802610 01/23/2024

  • (Tosh DK, Pavan M, Cronin C, Pottie E, Wan TC, Chen E, Lewicki SA, Campbell RG, Gao ZG, Auchampach JA, Stove CP, Liang BT, Jacobson KA.) ACS Pharmacology and Translational Science. 12 July 2024;7(7):2154-2173 SCOPUS ID: 2-s2.0-85195801024 07/12/2024

  • (Tosh DK, Fisher CL, Salmaso V, Wan TC, Campbell RG, Chen E, Gao ZG, Auchampach JA, Jacobson KA.) ACS Pharmacol Transl Sci. 2023 Sep 08;6(9):1288-1305 PMID: 37705595 PMCID: PMC10496144 09/14/2023

  • (Gao ZG, Auchampach JA, Jacobson KA.) Purinergic Signal. 2023 Sep;19(3):523-550 PMID: 36538251 PMCID: PMC9763816 SCOPUS ID: 2-s2.0-85173914165 12/21/2022

  • (Wang X, Wan TC, Kulik KR, Lauth A, Smith BC, Lough JW, Auchampach JA.) Dis Model Mech. 2023 May 01;16(5) PMID: 36341679 PMCID: PMC9672930 SCOPUS ID: 2-s2.0-85141362492 11/08/2022

  • (Tosh DK, Fisher CL, Salmaso V, Wan TC, Campbell RG, Chen E, Gao ZG, Auchampach JA, Jacobson KA.) ACS Pharmacology and Translational Science. 8 September 2023;6(9):1288-1305 SCOPUS ID: 2-s2.0-85168520378 09/08/2023

  • (Fallot LB, Suresh RR, Fisher CL, Salmaso V, O'Connor RD, Kaufman N, Gao ZG, Auchampach JA, Jacobson KA.) J Med Chem. 2022 Nov 24;65(22):15238-15262 PMID: 36367749 PMCID: PMC10354740 SCOPUS ID: 2-s2.0-85141945462 11/12/2022

  • (Fisher CL, Fallot LB, Wan TC, Keyes RF, Suresh RR, Rothwell AC, Gao ZG, McCorvy JD, Smith BC, Jacobson KA, Auchampach JA.) ACS Pharmacol Transl Sci. 2022 Aug 12;5(8):625-641 PMID: 35983277 PMCID: PMC9380209 08/20/2022

  • (Auchampach J, Han L, Huang GN, Kühn B, Lough JW, O'Meara CC, Payumo AY, Rosenthal NA, Sucov HM, Yutzey KE, Patterson M.) Am J Physiol Heart Circ Physiol. 2022 Apr 01;322(4):H579-H596 PMID: 35179974 PMCID: PMC8934681 SCOPUS ID: 2-s2.0-85127729067 02/19/2022

  • (Tosh DK, Salmaso V, Campbell RG, Rao H, Bitant A, Pottie E, Stove CP, Liu N, Gavrilova O, Gao ZG, Auchampach JA, Jacobson KA.) Eur J Med Chem. 2022 Jan 15;228:113983 PMID: 34844790 PMCID: PMC8865922 SCOPUS ID: 2-s2.0-85120162519 12/01/2021

Publications of from the